SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

2/13/24 1:34:34 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PRLD alert in real time by email

SC 13G/A 1 PRELUDE_4Q2023_Exit.txt EXIT FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Exit Filing) Prelude Therapeutics Inc (Name of Issuer) ----------------------------------------------------------- Class A Common Shares, par value $0.0001 per share (Title of Class of Securities) ----------------------------------------------------------- 74065P101 (CUSIP Number) ----------------------------------------------------------- December 31, 2023 Date of Event Which Requires Filing of this Statement ----------------------------------------------------------- Check the appropriate box to designate the rule pursuant to which this Schedule is filed: /x/ Rule 13d-1(b) / / Rule 13d-1(c) / / Rule 13d-1(d) *TThe remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 1. Names of reporting persons UBS Group AG (for the benefit and on behalf of the UBS Asset Management division of UBS Group AG (see Item 7) ----------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group a / / b / / See Item 8 of attached schedule ----------------------------------------------------------- 3. SEC USE ONLY ----------------------------------------------------------- 4. Citizenship or Place of Organization Switzerland ----------------------------------------------------------- Number of 5. Sole Voting Power 0 Shares Bene- 6. Shared Voting Power 0 ficially 7. Sole Dispositive Power 0 Owned by Each 8. Shared Dispositive Power 0 Reporting Person With: ----------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person: 0 ----------------------------------------------------------- 10. Check if the Aggregate Amount in Row 9 Excludes Certain Shares / / ----------------------------------------------------------- 11. Percent of Class Represented by Amount in Row 9 0% ----------------------------------------------------------- 12. Type of reporting person (see instructions) HC ----------------------------------------------------------- Item 1(a) Name of issuer: Prelude Therapeutics Inc ----------------------------------------------------------- Item 1(b) Address of issuer's principal executive offices: Prelude Therapeutics Inc 200 Powder Mill Road Wilmington, DE 19803 ----------------------------------------------------------- 2(a) Name of person filing: UBS Group AG ----------------------------------------------------------- 2(b) Address or principal business office or, if none, residence: UBS Group AG Bahnhofstrasse 45 PO Box CH-8021 Zurich, Switzerland ----------------------------------------------------------- 2(c) Citizenship: Switzerland ----------------------------------------------------------- 2(d) Title of class of securities: Common stock, par value $0.0001 per share ----------------------------------------------------------- 2(e) CUSIP No.: 74065P101 ----------------------------------------------------------- Item 3. If this statement is filed pursuant to Sections 240.13d 1(b) or 240.13d 2(b) or (c), check whether the person filing is a: (a) / / Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) / / Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) / / Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) / / Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a 8); (e / / An investment adviser in accordance with Section 240.13d 1(b)(1)(ii)(E); (f) / / An employee benefit plan or endowment fund in accordance with Section 240.13d 1(b)(1)(ii)(F); (g) /X/ A parent holding company or control person in accordance with Section 240.13d 1(b)(1)(ii)(G); (h) / / A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) / / A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a 3); (j) / / A non-U.S. institution in accordance with Section 240.13d 1(b)(1)(ii)(J); (k) / / Group, in accordance with Section 240.13d 1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d 1(b)(1)(ii)(J), please specify the type of institution: ________________________________ ----------------------------------------------------------- Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 0 (b) Percent of class: 0% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 0. (ii) Shared power to vote or to direct the vote ____. (iii) Sole power to dispose or to direct the disposition of ___. (iv) Shared power to dispose or to direct the disposition of 0. ----------------------------------------------------------- Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following / /. Dissolution of a group requires a response to this item. Item 6. Ownership of More than 5 Percent on Behalf of Another Person. Accounts managed on a discretionary basis by the UBS Asset Management division of UBS Group AG (UBS AM) have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities. To the best of our knowledge, no account holds more than 5 percent of the outstanding securities being reported in this filing. ----------------------------------------------------------- Item 6. Ownership of More than Five Percent on Behalf of Another Person: Accounts managed on a discretionary basis by the UBS Asset Management division of UBS Group AG (UBS AM) have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities. To the best of our knowledge, no account holds more than 5 percent of the outstanding securities being reported in this filing. ----------------------------------------------------------- Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Identification: UBS Asset Management (Americas) Inc. Classification: IA In addition to UBS Group AG, the following UBS Asset Management affiliates and subsidiaries are part of the UBS Asset Management division included in this filing: UBS Asset Management (Americas) Inc., UBS Asset Management (Canada) Inc., UBS Asset Management (Deutschland) GmbH, UBS Asset Management (Japan) Ltd, UBS Asset Management (Singapore) Ltd, UBS Asset Management (UK) Limited, UBS Fund Management (Luxembourg) S.A., and UBS Fund Management (Switzerland) AG ----------------------------------------------------------- Item 8. Identification and Classification of Members of the Group. UBS AM is composed of wholly-owned subsidiaries and branches of UBS Group AG. UBS Group AG is reporting direct and indirect beneficial ownership of holdings. None of the reporting persons affirm the existence of a group within the meaning of Rule 13d 5(b)(1). ----------------------------------------------------------- Item 9. Notice of Dissolution of Group. N/A ----------------------------------------------------------- Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under Section 240.14a 11. Signatures After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: 02/13/2024 UBS Asset Management (Americas), Inc. Signature: /s/ Lissette Resnick Name: Lissette Resnick Title: Director Date: 02/13/2024 Signature: /s/ Barry J. Mullen Name: Barry J. Mullen Title: Chief Compliance Officer

Get the next $PRLD alert in real time by email

Recent Analyst Ratings for

$PRLD

Date	Price Target	Rating	Analyst
9/19/2024	$5.00	Neutral → Buy	H.C. Wainwright
6/20/2024	$3.00	Equal Weight → Underweight	Barclays
3/13/2024	$7.00	Mkt Outperform	JMP Securities
2/20/2024	$5.00	Buy → Neutral	H.C. Wainwright
12/19/2023	$10.00 → $4.00	Equal-Weight → Underweight	Morgan Stanley
11/21/2022	$8.00 → $6.00	Neutral → Underperform	BofA Securities
9/9/2022	$19.00 → $11.00	Overweight → Equal-Weight	Morgan Stanley
7/29/2022	$9.00	Buy	Jefferies

More analyst ratings

SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

2/13/24 1:34:34 PM ET

$PRLD

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PRLD alert in real time by email

Recent Analyst Ratings for

$PRLD

Date	Price Target	Rating	Analyst
9/19/2024	$5.00	Neutral → Buy	H.C. Wainwright
6/20/2024	$3.00	Equal Weight → Underweight	Barclays
3/13/2024	$7.00	Mkt Outperform	JMP Securities
2/20/2024	$5.00	Buy → Neutral	H.C. Wainwright
12/19/2023	$10.00 → $4.00	Equal-Weight → Underweight	Morgan Stanley
11/21/2022	$8.00 → $6.00	Neutral → Underperform	BofA Securities
9/9/2022	$19.00 → $11.00	Overweight → Equal-Weight	Morgan Stanley
7/29/2022	$9.00	Buy	Jefferies

More analyst ratings

SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $PRLD

SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for $PRLD

$PRLD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Prelude Therapeutics upgraded by H.C. Wainwright with a new price target

Prelude Therapeutics downgraded by Barclays with a new price target

JMP Securities initiated coverage on Prelude Therapeutics with a new price target

$PRLD Press Releases

Fastest customizable press release news feed in the world

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

$PRLD Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Chemistry Officer Combs Andrew bought $69,250 worth of shares (100,000 units at $0.69), increasing direct ownership by 26% to 480,123 units (SEC Form 4)

CEO Vaddi Krishna bought $467,438 worth of shares (675,000 units at $0.69), increasing direct ownership by 51% to 1,999,296 units (SEC Form 4)

CEO Vaddi Krishna bought $14,909 worth of shares (20,416 units at $0.73), increasing direct ownership by 2% to 1,324,296 units (SEC Form 4)

$PRLD SEC Filings

Amendment: SEC Form SCHEDULE 13D/A filed by Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

Amendment: SEC Form SCHEDULE 13G/A filed by Prelude Therapeutics Incorporated

$PRLD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Baker Bros. Advisors Lp

SEC Form 3 filed by new insider Scherer Paul C

SEC Form 4 filed by Director Sandor Victor

$PRLD Leadership Updates

Live Leadership Updates

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

Prelude Therapeutics Reports Full Year 2021 Financial Results

Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer

$PRLD Financials

Live finance-specific insights

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update

$PRLD Large Ownership Changes

This live feed shows all institutional transactions in real time.